DexCom (NASDAQ:DXCM) EVP Jon Coleman Sells 4,911 Shares

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,911 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $74.13, for a total transaction of $364,052.43. Following the completion of the transaction, the executive vice president directly owned 95,450 shares in the company, valued at approximately $7,075,708.50. The trade was a 4.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Wednesday, June 3rd, Jon Coleman sold 4,912 shares of DexCom stock. The shares were sold at an average price of $73.00, for a total transaction of $358,576.00.

DexCom Stock Performance

Shares of DXCM stock traded up $0.27 during mid-day trading on Friday, reaching $72.86. 4,672,514 shares of the company’s stock traded hands, compared to its average volume of 5,348,739. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95. The firm has a market capitalization of $28.11 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $89.98. The firm has a 50 day moving average price of $64.71 and a two-hundred day moving average price of $66.94.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.09. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. During the same period last year, the firm earned $0.32 EPS. DexCom’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, research analysts forecast that DexCom, Inc. will post 2.57 EPS for the current year.

Institutional Investors Weigh In On DexCom

Institutional investors and hedge funds have recently modified their holdings of the company. Reflection Asset Management purchased a new position in shares of DexCom in the 4th quarter valued at about $25,000. Ascentis Independent Advisors purchased a new position in DexCom in the 1st quarter valued at about $25,000. CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. MCF Advisors LLC acquired a new stake in DexCom in the 4th quarter worth about $32,000. Finally, ORG Partners LLC increased its stake in DexCom by 124.3% during the 4th quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after buying an additional 281 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on DXCM shares. Robert W. Baird set a $80.00 price objective on shares of DexCom in a research note on Friday, May 1st. Bank of America lowered their price target on shares of DexCom from $100.00 to $80.00 and set a “buy” rating for the company in a report on Monday, May 18th. Wells Fargo & Company dropped their price target on DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday, February 13th. Piper Sandler reissued an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Finally, Barclays reiterated an “underweight” rating and issued a $64.00 target price (down from $67.00) on shares of DexCom in a report on Monday, May 18th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $82.63.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.